IE921990A1 - Medicaments - Google Patents

Medicaments

Info

Publication number
IE921990A1
IE921990A1 IE199092A IE921990A IE921990A1 IE 921990 A1 IE921990 A1 IE 921990A1 IE 199092 A IE199092 A IE 199092A IE 921990 A IE921990 A IE 921990A IE 921990 A1 IE921990 A1 IE 921990A1
Authority
IE
Ireland
Prior art keywords
tetrahydro
benzazepine
compound
hydroxy
methoxy
Prior art date
Application number
IE199092A
Other languages
English (en)
Inventor
John Gerard Ward
Rodney Christopher Young
Alberto Julio Kaumann
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919113379A external-priority patent/GB9113379D0/en
Priority claimed from GB919113377A external-priority patent/GB9113377D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IE921990A1 publication Critical patent/IE921990A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IE199092A 1991-06-21 1992-07-01 Medicaments IE921990A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113379A GB9113379D0 (en) 1991-06-21 1991-06-21 Medicaments
GB919113377A GB9113377D0 (en) 1991-06-21 1991-06-21 Medicaments

Publications (1)

Publication Number Publication Date
IE921990A1 true IE921990A1 (en) 1992-12-30

Family

ID=26299102

Family Applications (1)

Application Number Title Priority Date Filing Date
IE199092A IE921990A1 (en) 1991-06-21 1992-07-01 Medicaments

Country Status (9)

Country Link
EP (1) EP0589973A1 (fr)
JP (1) JPH06508352A (fr)
KR (1) KR940701258A (fr)
AU (1) AU1927992A (fr)
CA (1) CA2110575A1 (fr)
IE (1) IE921990A1 (fr)
MX (1) MX9203012A (fr)
PT (1) PT100602A (fr)
WO (1) WO1993000094A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
CA2250186A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Technique de traitement de la douleur due a la migraine
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
RU2423353C1 (ru) 2002-12-20 2011-07-10 Глэксо Груп Лимитед Новые производные бензазепина
PL2332921T3 (pl) 2003-06-17 2016-08-31 Arena Pharm Inc Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny
EP2332920A3 (fr) 2003-06-17 2011-12-21 Arena Pharmaceuticals, Inc. Procédés de préparation de 3-benzazepines
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
CN101084193B (zh) 2004-12-21 2011-12-07 艾尼纳制药公司 (r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓盐酸盐的晶型
SG158168A1 (en) 2004-12-23 2010-01-29 Arena Pharm Inc 5ht2c receptor modulator compositions and methods of use
JP5199997B2 (ja) 2006-04-03 2013-05-15 アリーナ ファーマシューティカルズ， インコーポレイテッド ８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
ES2522587T3 (es) 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
US8822727B2 (en) 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
WO2010148207A2 (fr) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Procédés pour la préparation d'agonistes du récepteur 5-ht2c
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
JP6272695B2 (ja) 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
CA2808900A1 (fr) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Formes posologiques a dissolution rapide d'agonistes de 5-ht2c
WO2012030938A1 (fr) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Sels de lorcasérine dotés d'acides optiquement actifs
EP2611449A1 (fr) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Administration de lorcasérine à des individus présentant une insuffisance rénale
CN103189360A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
UY34436A (es) 2012-10-09 2014-07-31 Arena Pharm Inc Metodo de control del peso

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659706A (en) * 1985-12-20 1987-04-21 Smithkline Beckman Corporation Sulfinyl and sulfonyl substituted 3-benzazepines

Also Published As

Publication number Publication date
CA2110575A1 (fr) 1993-01-07
JPH06508352A (ja) 1994-09-22
AU1927992A (en) 1993-01-25
MX9203012A (es) 1993-07-01
WO1993000094A3 (fr) 1993-03-04
EP0589973A1 (fr) 1994-04-06
WO1993000094A2 (fr) 1993-01-07
PT100602A (pt) 1993-09-30
KR940701258A (ko) 1994-05-28

Similar Documents

Publication Publication Date Title
IE921990A1 (en) Medicaments
AU2002228007B2 (en) Indole derivatives and their use as 5-HT2b and 5-HT2c receptor ligands
KR910000251B1 (ko) 비시클로 치환된 페닐아세토니트릴 유도체
US4520025A (en) Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
CZ398191A3 (en) Novel 4-amino alkyl-2(3h)-indolones and pharmaceutical compositions containing them
SK3612000A3 (en) Sustained release tablet formulation to treat parkinson disease
EP1206264A2 (fr) Compositions et procedes permettant de traiter l'intolerance aux opiaces
AU2014323822B2 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
WO1999020620A1 (fr) Derive d'isoquinoleine et medicament
WO2000028993A1 (fr) Ligands de serotonine en tant que composes favorisant l'erection
KR20130112848A (ko) 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
HU201731B (en) Process for producing substituted benzamides and pharmaceutical compositions comprising such active ingredient
JPWO2005079845A1 (ja) 片頭痛予防薬
JPH06506442A (ja) １−（４−アシルアミノフェニル）−７，８−メチレンジオキシ−５ｈ−２，３−ベンゾ−ジアゼピン誘導体及びその酸付加塩、それを含む製薬学的組成物及びその製造方法
JPS62226963A (ja) 選択的アルフア−アドレナリン受容体きつ抗剤
JPH08283247A (ja) １−［２−（置換ビニル）］−３，４−ジヒドロ−５ｈ−２，３−ベンゾジアゼピン誘導体
JPS62265270A (ja) 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
EP0382618B1 (fr) Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
EP0382628B1 (fr) Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
JP4216337B2 (ja) ベンゾ［ｇ］キノリン誘導体
EA003991B1 (ru) Производные 2-аминопиридинов, способ ингибирования синтазы оксида азота, фармацевтические композиции и способы лечения
CZ321095A3 (en) Heterocyclic compounds
KR20020012314A (ko) 빈뇨 혹은 요실금의 치료 또는 예방제
KR100408364B1 (ko) 3(2에이치)-피리다지논유도체및이들화합물을함유하는제약학적인조성물
KR20030002304A (ko) 3-페닐-3,7-디아자비시클로[3.3.1]노난 화합물들과 이들의제조방법 및 이러한 화합물들을 포함하는 약제들

Legal Events

Date Code Title Description
FC9A Application refused sect. 31(1)